Quotes 5-day view End-of-day quote Shenzhen Stock Exchange
05/23/2022
05/24/2022
05/25/2022
05/26/2022
05/27/2022
Date
47.28
44.61
45
44.94
44.18
Last
3371775
3586811
2217759
2040470
2932074
Volume
+4.49%
-5.65%
+0.87%
-0.13%
-1.69%
Change
Estimated financial data (e) CNY USD
Sales 2022
2 819 M
421 M
421 M
Net income 2022
442 M
65,9 M
65,9 M
Net cash position 2022
853 M
127 M
127 M
P/E ratio 2022
41,5x
Yield 2022
0,77%
Sales 2023
3 966 M
592 M
592 M
Net income 2023
725 M
108 M
108 M
Net cash position 2023
1 400 M
209 M
209 M
P/E ratio 2023
25,3x
Yield 2023
1,36%
Capitalization
18 352 M
2 739 M
2 739 M
EV / Sales 2022
6,21x
EV / Sales 2023
4,27x
Nbr of Employees
1 677
Free-Float
48,1%
Betta Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the research and development, manufacturing, sales and marketing of drugs to treat malignant tumors, diabetes, cardiovascular and cerebrovascular diseases. The Company’s core product is icotinib, which is a kind of antineoplastic agent. Its products also include burn pain relieving plaster, oryzanol vitamin B1 and vitamin B6 tablets....
Ratings of Betta Pharmaceuticals Co., Ltd.
All news about BETTA PHARMACEUTICALS CO., LTD.
05/23 Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 202.. CI
05/04 EyePoint Pharmaceuticals Grants Betta Pharmaceuticals Rights to Commercialize Chronic E.. MT
04/29 Betta Pharmaceuticals Co., Ltd. Approves 2021 Profit Distribution Plan CI
04/26 Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended Ma.. CI
04/25 Zhejiang Shimai Pharmaceutical Co., Ltd. announced that it has received CNY 30 million .. CI
04/07 Betta Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2021 CI
04/06 Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended Decemb.. CI
04/04 Wuhan Healthgen Biotechnology Corp. announced that it has received CNY 464.999997 milli.. CI
03/04 Wuhan Healthgen Biotechnology Corp. announced that it expects to receive CNY 464.999997.. CI
01/23 Zhejiang Shimai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 mi.. CI
2021 JL Mag Rare-Earth Testing Waters for $200 Million Hong Kong IPO MT
2021 Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended Sept.. CI
2021 Hangzhou Neoantigen Biotechnology co., LTD. announced that it has received $3.1 million.. CI
2021 Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 3.. CI
2021 MARKET CHATTER : JL Mag Rare-Earth Files for $200 Million Hong Kong IPO; Shares Jump 3%MT
News in other languages on BETTA PHARMACEUTICALS CO., LTD.
Chart BETTA PHARMACEUTICALS CO., LTD.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BETTA PHARMACEUTICALS CO., LTD.
Short Term Mid-Term Long Term Trends Bullish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
44,18 CNY
Average target price
85,80 CNY
Spread / Average Target
94,2%
Please enable JavaScript in your browser's settings to use dynamic charts.